Journal of Neuro-Oncology

, Volume 114, Issue 1, pp 117–125 | Cite as

Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer

  • Saurabh Ray
  • Stacey Dacosta-ByfieldEmail author
  • Arijit Ganguli
  • Vijayveer Bonthapally
  • April Teitelbaum
Clinical Study


Brain metastases are a frequent complication of many systemic cancers and portend a poor prognosis. This retrospective analysis of health claims data compared survival, treatment and health care utilization and costs in patients with brain metastasis by primary tumor site. Adult commercial and Medicare Advantage enrollees newly diagnosed with brain metastasis in 01 Jan 2004 through 30 Apr 2010 were identified. Inclusion required at least 2 claims that identified the same primary cancer site prior to diagnosis of brain metastasis and no evidence of primary brain tumors. Health care utilization rates and costs were calculated at the patient level for each month of follow-up. Differences among primary cancer site cohorts were assessed by ANOVA (continuous variables), Chi square test (proportions) and the Poisson distribution (utilization rates). The primary cancer cohorts comprised 1,031 lung cancer, 93 melanoma and 395 female breast cancer patients. During the 6 months prior to brain metastasis diagnosis, 59 % of lung cancer patients had no evidence of lymph node involvement or other metastatic disease compared to 55 and 42 % of melanoma and breast cancer patients (P < 0.001). Survival after brain metastasis diagnosis was less than 3 months for 52, 43 and 39 % for lung cancer, breast cancer and melanoma, respectively (P < 0.001). Melanoma patients had the highest rate of inpatient stays and outpatient visits (P ≤ 0.003). Total monthly all-cause costs were: melanoma, $23,426; breast cancer $19,708; lung cancer, $17,007 (P = 0.003). Health care utilization and costs after brain metastasis diagnosis were substantial and differed by primary tumor site.


Brain metastasis Primary tumor Burden of illness Cost Survival 



Medical writing support was provided by Sarah Peirce-Sandner, MS, at OptumInsight and was funded by Abbott Laboratories.

Conflict of Interest

Support for this study was provided by Abbott Laboratories. Stacey Dacosta-Byfield and April Teitelbaum are or were employees of OptumInsight, Eden Prairie, MN and were paid consultants to Abbott Laboratories in connection with this study and development of this manuscript.


  1. 1.
    Gori S, Rimondini S, De Angelis V et al (2007) Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12:766–773PubMedCrossRefGoogle Scholar
  2. 2.
    Mamon HJ, Yeap BY, Janne PA et al (2005) High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 23:1530–1537PubMedCrossRefGoogle Scholar
  3. 3.
    Davies MA, Liu P, McIntyre S et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:1687–1696PubMedCrossRefGoogle Scholar
  4. 4.
    Eichler AF, Loeffler JS (2007) Multidisciplinary management of brain metastases. Oncologist 12:884–898PubMedCrossRefGoogle Scholar
  5. 5.
    Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14PubMedCrossRefGoogle Scholar
  6. 6.
    Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI (1999) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795–803PubMedCrossRefGoogle Scholar
  7. 7.
    Tsao MN, Lloyd N, Wong RK et al (2012) Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane database Syst Rev 4:CD003869PubMedGoogle Scholar
  8. 8.
    Pollock BE, Brown PD, Foote RL, Stafford SL, Schomberg PJ (2003) Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J Neurooncol 61:73–80PubMedCrossRefGoogle Scholar
  9. 9.
    Nieder C, Norum J, Stemland JG, Dalhaug A (2010) Resource utilization in patients with brain metastases managed with best supportive care, radiotherapy and/or surgical resection: a Markov analysis. Oncology 78:348–355PubMedCrossRefGoogle Scholar
  10. 10.
    Bennett CL, Tigue CC, Fitzner KA (2007) The economics of brain metastases. Cancer Treat Res 136:23–29PubMedCrossRefGoogle Scholar
  11. 11.
    Ganguli A, Henk H, Teitelbaum A, Ray S (2011) Burden of Brain Metastasis in a Metastatic Non-small Cell Lung Cancer (NSCLC) Population. Poster presented at International Society for Pharmacoeconomics and Outcomes Research 14th Annual European Congress, Madrid, Spain, 5–8 November, 2011Google Scholar
  12. 12.
    Pelletier EM, Shim B, Goodman S, Amonkar MM (2008) Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat 108:297–305PubMedCrossRefGoogle Scholar
  13. 13.
    US Department of Health and Human Services. Health Insurance Portability and Accountability Act of 1996. Public Law 104–191, 104th Congress. Accessed 27 October 2012
  14. 14.
    Quan H, Sundararajan V, Halfon P et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139PubMedCrossRefGoogle Scholar
  15. 15.
    US Department of Health and Human Services. Consumer Price Index–Chained Consumer Price Index. Accessed 27 October 2012
  16. 16.
    Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22:2865–2872PubMedCrossRefGoogle Scholar
  17. 17.
    Lassman AB, DeAngelis LM (2003) Brain metastases. Neurol Clin 21:1–23, viiPubMedCrossRefGoogle Scholar
  18. 18.
    Hillner BE, Kirkwood JM, Agarwala SS (2001) Burden of illness associated with metastatic melanoma: an audit of 100 consecutive referral center cases. Cancer 91:1814–1821PubMedCrossRefGoogle Scholar
  19. 19.
    Staudt M, Lasithiotakis K, Leiter U et al (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213–1218PubMedCrossRefGoogle Scholar
  20. 20.
    Pestalozzi BC, Zahrieh D, Price KN et al (2006) Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935–944PubMedCrossRefGoogle Scholar
  21. 21.
    Arrieta O, Saavedra-Perez D, Kuri R et al (2009) Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer 9:119PubMedCrossRefGoogle Scholar
  22. 22.
    Carey LA, Ewend MG, Metzger R et al (2004) Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat 88:273–280PubMedCrossRefGoogle Scholar
  23. 23.
    Gonzalez-Angulo AM, Cristofanilli M, Strom EA et al (2004) Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101:1760–1766PubMedCrossRefGoogle Scholar
  24. 24.
    Eigentler TK, Figl A, Krex D et al (2011) Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117:1697–1703PubMedCrossRefGoogle Scholar
  25. 25.
    Fife KM, Colman MH, Stevens GN et al (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293–1300PubMedCrossRefGoogle Scholar
  26. 26.
    Daryanani D, Plukker JT, de Jong MA et al (2005) Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res 15:119–124PubMedCrossRefGoogle Scholar
  27. 27.
    Villa S, Weber DC, Moretones C et al (2011) Validation of the new graded prognostic assessment scale for brain metastases: a multicenter prospective study. Radiat Oncol 6:23PubMedCrossRefGoogle Scholar
  28. 28.
    Ono M, Ando M, Yunokawa M et al (2009) Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol 14:48–52PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Saurabh Ray
    • 1
  • Stacey Dacosta-Byfield
    • 2
    Email author
  • Arijit Ganguli
    • 1
  • Vijayveer Bonthapally
    • 1
  • April Teitelbaum
    • 2
  1. 1.Abbott LaboratoriesAbbott ParkUSA
  2. 2.OptumInsightEden PrairieUSA

Personalised recommendations